A process for preparing lactobacillus-based recombinant vaccine candidate against multiple salmonella serovar in poultry

The Lactobacillus-based recombinant vaccine addresses Salmonella infections in poultry by using Lactobacillus plantarum NC8 as a live vector to express conserved antigens, achieving high efficacy and broad protection against Salmonella serovars, including reducing zoonotic transmission.

WO2025202803A1 Publication Date: 2025-10-02AHMAD SYED MUDASIR +8
0 Cites 1 Cited by

Patent Information

Application Number
PCT/IB2025/052370
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-03-26
Filing Date
2025-03-05
Publication Date
2025-10-02

AI Technical Summary

Technical Problem

Current vaccination strategies for Salmonella infections in poultry are inadequate, leading to economic losses and potential health risks, and there is a need for a broad-spectrum defense against various Salmonella serovars that addresses antigenic variability.

Method used

A Lactobacillus-based recombinant vaccine using genetically modified Lactobacillus plantarum NC8 as a live vector, expressing conserved Salmonella antigens (PagN, SopE2, and FliC) with a robust constitutive promoter (phosphoglycerate mutase, pgm) and Anchor sequences (Signal Lp_2145 and cAM12) for enhanced surface expression, administered orally to induce mucosal immunity.

Benefits of technology

The vaccine achieves over 95% efficacy in preventing Salmonella infections, reduces vertical transmission, and demonstrates broad protection against multiple serovars, including Salmonella Typhimurium and Enteritidis, with potential to minimize zoonotic transmission.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The process comprises providing a recombinant vaccine construct, wherein said construct comprises genetically modified Lactobacillus plantarum NC8 as a live vector; modifying the genetic structure of said Lactobacillus plantarum NC8 to express conserved Salmonella antigens, including PagN, SopE2, and FliC, anchored by a ptrk 892 backbone with a constitutive promoter, phosphoglycerate mutase (PGM); incorporating Signal Lp_2145 and cAM12 Anchor sequences into said genetic construct to enhance surface expression of recombinant proteins on Lactobacillus plantarum NC8; administering said recombinant vaccine orally to poultry, leveraging the probiotic properties of Lactobacillus plantarum NC8 for effective colonization of the poultry gastrointestinal tract; inducing a prolonged and intensified immune response by ensuring sustained high-level expression of target antigens through the utilization of the robust constitutive promoter, phosphoglycerate mutase (PGM); and optimizing immunogenicity through the surface expression of recombinant proteins on Lactobacillus plantarum NC8, fostering a robust and precisely targeted immune response.
Need to check novelty before this filing date? Find Prior Art